
According to the Zhitong Finance App, Beihai Kangcheng-B (01228) announced that Gorenin® (injectable veraginase beta) (Gorenine) and Melibe® (clomaxibat oral solution) (Melibe) have been included in the cost schedule issued by the China Association of Actuaries on November 10, 2026. The cost schedule covers 117 drugs in various treatment fields such as tumors, rare diseases, and chronic diseases, and aims to consolidate the guaranteed pricing foundation for innovative drugs. Both Gorenin and Miley's were selected for this cost schedule, which covered the three rare disease indications of Gaucher disease and Alagerie syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), respectively, which are expected to benefit rare disease groups using commercial insurance channels to reduce the burden of medication use.
Gorenin was approved for marketing by China's National Drug Administration (China Drug Administration) on May 13, 2025. It is the first domestically developed long-term enzyme replacement therapy for adolescents aged 12 and above and adults with type I and III Gaucher disease. As a bioinnovative drug, Gorenin can replace similar imported products, and terminal treatment costs are expected to be significantly reduced. It is expected to greatly reduce the financial burden of long-term treatment on patients and fundamentally improve the accessibility and sustainability of medication for patients with Gaucher disease around the world. The company holds exclusive global rights to develop and commercialize this product, and its first stop overseas has landed in the growing North African market. Furthermore, the company is currently carrying out a registered clinical trial approved by the State Drug Administration to expand the application of Gorenin to children aged 2 and under 12.
Melebe is an ileo-bile acid transporter inhibitor that is hardly absorbed. It blocks the enterohepatic circulation of bile acid, lowers bile acid levels in the liver and serum, reduces liver damage mediated by this, and relieves cholestatic itching (extreme itching). As the first product approved for ALGS and PFIC treatment for 3 months or more in China, Mileby began commercialization in mainland China in 2024. Up to now, it has been covered by welfare insurance in 64 cities, covering 299 million people in China. On August 14, 2026, Malibi was approved by the Taiwan Health Insurance Department to be included in health insurance payments, and it officially came into effect on September 1, 2026.
The company believes that the inclusion of Gorening and Miley in the cost schedule marks the company's phased progress in promoting the accessibility of multi-level coverage for rare diseases, and also provides basic pricing information that can be used as a reference for commercial health insurance product design. The company looks forward to using this industrial platform to open up commercial insurance protection channels and further enhance the accessibility of medication for patients with rare diseases.